TMJ or Jaw Pain From a MAD: What Resolves and What Persists

By Dr. Boris Zusin · Published September 5, 2026

Jaw-joint (TMJ) and jaw-muscle soreness are among the most common things patients notice after starting mandibular advancement device (MAD) therapy — and for most people, it's a phase, not a permanent feature of treatment. But it's not the whole story: a specific, identifiable minority of patients continue to have jaw pain or joint symptoms years into therapy, and this persistence — not any lasting physical damage to the joint itself — turns out to be one of the leading reasons patients quit MAD therapy altogether. Knowing which pattern you're likely to fall into, and why, is worth understanding before jaw discomfort becomes a reason to give up on an otherwise-working treatment.

The Overall Trajectory: A Spike, Then Resolution, for Most Patients

Across several controlled studies, the pattern is consistent: pain-related jaw-joint symptoms spike during the initial fitting and titration period, then decline. In one two-year controlled comparison against CPAP, pain-related TMD symptoms were markedly more common in the oral-appliance group only during the initial treatment period (24% versus 6% with CPAP) — over the full follow-up, these symptoms were characterized as generally mild and transient, with no lasting limitation in jaw function in either group. A separate cohort using structured TMD diagnostic criteria tracked this same arc directly: TMD prevalence fell from about 20% at the start of treatment to about 8% by the final visit, after some fluctuation along the way, with the signs observed described as most likely transient. That same study found something reassuring for patients who already have jaw issues before starting: pre-existing TMD was not meaningfully made worse by MAD use. A systematic review and meta-analysis reached the same conclusion at a larger scale — patients with pre-existing TMD signs and symptoms generally don't see significant exacerbation, which is why TMD by itself isn't considered a routine reason to avoid MAD therapy.

What Genuinely Persists Long-Term

That said, "usually resolves" isn't "always resolves," and the honest picture includes a real subset of patients for whom it doesn't. A 3-year prospective study found that joint sounds (clicking, popping) fluctuated over time without a significant net change, and CBCT imaging showed no significant progression of bony joint changes — interpreted as the joint adaptively remodeling rather than being damaged. But soreness and pain in the jaw joints and chewing muscles was the primary reason patients dropped out of that same study, and the dropout rate was strikingly high: 29 of 43 patients left the study over the 3-year period. A broader systematic review found individual long-term studies diverge from each other in telling ways: one found clicking and muscle tenderness on palpation remained present throughout the study period (while a different sign, crepitus, actually improved); a separate 5-year study using structured diagnostic criteria, in patients who already had TMD at baseline, found TMD symptoms and severity essentially unchanged with MAD use; and others reported headaches persisting for roughly a year, and TMJ pain that persisted at 75% jaw advancement but resolved once the advancement was reduced to 50%. Part of the explanation offered for this mixed picture is that TMD has its own natural history independent of MAD therapy — it commonly starts in early adulthood and fluctuates on its own into middle age, an age range that overlaps substantially with typical MAD patients, so not every persistent symptom is necessarily caused by the appliance itself.

Who's Actually at Risk for Symptoms That Persist

This is the most clinically useful part of the picture: a 2026 cohort of 469 patients with pain data found that 20% reported jaw pain related to oral appliance therapy, and what predicted it wasn't sleep apnea severity or basic demographics — it was a cluster of features pointing to a pre-existing pain phenotype. Compared to patients without persistent pain, those who developed it were more likely to have had jaw pain before starting treatment (34% vs. 16%), tenderness in the chewing muscles on exam, fibromyalgia (15% vs. 8%), a history of headaches (42% vs. 27%), a history of jaw noises, limited jaw opening, and habitual teeth clenching or grinding. Patients with a specific bite pattern — Angle Class II Division 1 — had roughly double the odds of developing pain. Notably, BMI, apnea severity (AHI), and breathing-event frequency (RDI) were not significant predictors — in other words, this isn't a dose-response relationship with how bad your sleep apnea is, it's about whether you're carrying an underlying vulnerability to jaw pain going in.

Why It's Muscle Trouble More Than Joint Damage

Biomechanical modeling helps explain why persistent symptoms tend to be muscular and functional rather than structural. That research found that as jaw advancement increases, the chewing muscles have to generate meaningfully more force just to close the jaw — but stress inside the joint itself at rest didn't meaningfully rise regardless of how far the jaw was advanced. That lines up with the clinical picture: what tends to persist is muscle tenderness and pain, not measurable structural joint damage or a lasting loss of function. A separate one-year trial in 192 patients backs this up directly — no change in jaw mobility, bite function, or TMJ/muscle tenderness on exam, and morning headaches actually improved on average.

What This Means for You

If you're starting MAD therapy, it's worth having an honest conversation about your own baseline risk before you begin: pre-existing jaw pain, muscle tenderness, jaw noises, limited opening, frequent headaches, fibromyalgia, and clenching or grinding are all reasonable things to flag, since they identify patients who benefit from slower titration, closer initial monitoring, and earlier co-management with a TMD-trained dentist or physical therapist if symptoms don't settle on their own. If jaw pain does show up and persist, the most evidence-supported lever isn't stopping the appliance — it's reducing the amount of jaw advancement. In documented cases, reducing protrusion from 75% down to 50% resolved persistent TMJ pain, and because efficacy plateaus well before maximum protrusion anyway, backing off advancement usually doesn't mean sacrificing how well the appliance controls your apnea. The bigger-picture takeaway: ongoing jaw-joint and muscle monitoring at every follow-up matters, because persistent soreness is a real, common, and largely avoidable cause of patients quitting a treatment that's otherwise working — not a sign of permanent damage to the joint itself.

If you're dealing with ongoing jaw or TMJ discomfort on a MAD, or you have a history of jaw pain and want that factored into your titration plan from the start, that's exactly the conversation to have before or during treatment — not after you've already decided to stop.